Exact Mass: 541.3084633999999

Exact Mass Matches: 541.3084633999999

Found 320 metabolites which its exact mass value is equals to given mass value 541.3084633999999, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Psychosine sulfate

{[(2S,4R,5S,6S)-6-{[(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methoxy}sulphonic acid

C24H47NO10S (541.2920522000001)

psychosine sulfate is a intermediate in the biosynthesis of cerebrosides. It is one of the products involved in the reaction of 3-phosphoadenylyl sulfate with galactosylsphingosine catalyzed by psychosine sulfotransferase, and the other product is ADP respectively. psychosine sulfate is a intermediate in the biosynthesis of cerebrosides.

Anopterine

C31H43NO7 (541.3039368)

Novapikromycin

(3R,5R,6S,7S,9R,11E,13S,14R)-13-hydroxy-14-[(1R)-1-hydroxyethyl]-3,5,7,9,13-pentamethyl-2,4,10-trioxooxacyclotetradec-11-en-6-yl 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranoside

C28H47NO9 (541.3250652)

A macrolide antibiotic that is biosynthesised by Streptomyces venezuelae.

LysoPC(20:5)

(2-{[(2R)-2-hydroxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyloxy]propyl phosphono]oxy}ethyl)trimethylazanium

C28H48NO7P (541.3168228)

LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position. The eicosapentaenoic acid moiety is derived from fish oils, liver and kidney. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position. The eicosapentaenoic acid moiety is derived from fish oils, liver and kidney. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.

CDDO-Im

(4aR,6aR,6aS,6bR,8aS,12aS,14bS)-8a-(imidazole-1-carbonyl)-4,4,6a,6b,11,11,14b-heptamethyl-3,13-dioxo-4a,5,6,6a,7,8,9,10,12,12a-decahydropicene-2-carbonitrile

C34H43N3O3 (541.3304248000001)

1-Isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-1H-indazole-4-carboxamide

N-[(6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl]-6-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-1-(propan-2-yl)-1H-indazole-4-carboxamide

C31H39N7O2 (541.3165074)

Lysosulfatide

{2-[(2-amino-3-hydroxyoctadec-4-en-1-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl}oxidanesulfonic acid

C24H47NO10S (541.2920522000001)

Pegaptanib

2,6-Bis({[hydroxy(2-methoxyethoxy)methylidene]amino})-N-(7-{[hydroxy(methyl)phosphoryl]oxy}heptyl)hexanimidate

C22H44N3O10P (541.2764174)

S - Sensory organs > S01 - Ophthalmologicals > S01L - Ocular vascular disorder agents > S01LA - Antineovascularisation agents

Poststatin

2-[2-(3-amino-2-oxopentanamido)-N-(2,6-diamino-3,7-dimethyl-5-oxooctanoyl)-4-methylpentanamido]-3-methylbutanoic acid

C26H47N5O7 (541.3475312)

(6R)-6-{(1E,3E)-5-[(2S,3S,5R,6R)-5-{[(2Z,4S)-4-(acetyloxy)pent-2enoyl]amino}-3,6-dimethyltetrahydro-2H-pyran-2-yl]-3-methylpenta-1,3-dien-1-yl}-1-deoxy-4-C-(hydroxymethyl)hex-2-ulopyranose

C27H43NO10 (541.2886818000001)

C31H43NO7

C31H43NO7 (541.3039368)

14-benzoylnudicaulidine

C31H43NO7 (541.3039368)

14-Benzoylneoline

[11-ethyl-8,16-dihydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate

C31H43NO7 (541.3039368)

Glu His Arg Thr

(4S)-4-amino-4-{[(1S)-1-{[(1S)-4-carbamimidamido-1-{[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl}butyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}butanoic acid

C21H35N9O8 (541.260847)

Glu His Thr Arg

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-4-carboxybutanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C21H35N9O8 (541.260847)

Glu Arg His Thr

(4S)-4-amino-4-{[(1S)-4-carbamimidamido-1-{[(1S)-1-{[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}butyl]carbamoyl}butanoic acid

C21H35N9O8 (541.260847)

Glu Arg Thr His

(4S)-4-amino-4-{[(1S)-4-carbamimidamido-1-{[(1S,2R)-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-hydroxypropyl]carbamoyl}butyl]carbamoyl}butanoic acid

C21H35N9O8 (541.260847)

Glu Thr His Arg

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-4-carboxybutanamido]-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanoic acid

C21H35N9O8 (541.260847)

Glu Thr Arg His

(4S)-4-amino-4-{[(1S,2R)-1-{[(1S)-4-carbamimidamido-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}butyl]carbamoyl}-2-hydroxypropyl]carbamoyl}butanoic acid

C21H35N9O8 (541.260847)

Phe Phe Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]hexanamido]-3-hydroxybutanoic acid

C28H39N5O6 (541.2900194)

Phe Phe Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-3-hydroxybutanamido]hexanoic acid

C28H39N5O6 (541.2900194)

Phe Gly Arg Tyr

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-phenylpropanamido]acetamido}-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanoic acid